Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Experimental cancer treatments Stories

2013-09-26 08:27:31

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- NovaRx Corporation announced that the results from the randomized Phase III trial of Lucanix(®) (belagenpumatucel-L) will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam. The results will be presented by Dr. Giuseppe Giaccone in "Presidential Session I: Best and Late Breaking Abstracts" on 28 September 2013. The primary endpoint of improving overall survival in 532 patients was not met. However,...

2013-09-18 08:28:45

- Primary endpoint achieved while still recruiting SYDNEY, Sept. 18, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAK(TM) in the treatment of late stage melanoma patients (the CALM study). The Phase 2 trial is a single arm study being conducted at 10 US sites and is designed to investigate the safety and efficacy of intratumoral CAVATAK(TM) (Coxsackievirus A21) in 54 evaluable(1)...

2013-09-12 23:28:16

Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children’s Hospital, however, are looking into how those same types of common viruses can actually help treat a child who is diagnosed with certain cancers. Columbus, Ohio (PRWEB) September 12, 2013 Parents do everything they can to protect their children against all of the nasty germs floating...

2013-09-09 08:26:34

CALGARY, Sept. 9, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced final tumour response data from its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles. Of 25...

2013-09-03 08:27:25

SYDNEY, Sept. 3, 2013 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013. Financial Results Net cash used in operating activities for the Year $3.9 million Cash position at the end of the Year $5.1 million Reported loss $4.1 million Operational Highlights CAVATAK(TM) Phase II CALM Melanoma Clinical Trial (USA) Highlights...

2013-08-27 08:26:48

SYDNEY, Aug. 27, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA, OTCQX: VRACY) is pleased to announce that Dr Malcolm McColl, Chief Executive Officer will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference, Millennium Broadway Hotel, New York. The presentation, on Tuesday September 10, 2013 at 2pm, Eastern US time, will provide a company overview with a focus on the strong interim results from the Phase 2 clinical trial of Viralytics' lead...

2013-08-20 08:31:01

WORCESTER, Mass. and TORONTO, Aug. 20, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of follow up studies from a Phase I clinical trial of its immunotherapeutic agent AE37 in patients with prostate cancer. The Phase I study demonstrated that the compound is safe, well-tolerated, and generated a specific and robust immune response. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express Inc....

2013-07-31 12:27:21

HELSINKI, Finland, July 31, 2013 /PRNewswire/ -- Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus...

2013-07-29 08:25:43

Company Reports Strong Interim Data in Phase 2 Study Targeting Late-Stage Melanoma; Full Recruitment Expected by End of 2013 SYDNEY, July 29, 2013 /PRNewswire/ -- Viralytics Limited (ASX: VLA; OTC: VRACY), an oncolytic virotherapy company developing new drugs to treat a wide range of cancers, today announced that progress in its Phase 2 clinical trial of intratumourally administered CAVATAK(TM) for the treatment of late-stage melanoma (the CALM study) continues to accelerate with...

2013-07-19 23:01:51

Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed on his blog in depth recent discoveries by a small biotech firm in San Diego that has made significant advancement in cancer research. San Diego, CA (PRWEB) July 19, 2013 Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed in depth the discoveries by a small biotech firm in San Diego that has been flying under the radar for the past decade. What’s the big...